

Search

=> d his

(FILE 'HOME' ENTERED AT 18:03:36 ON 28 OCT 2004)

FILE 'REGISTRY' ENTERED AT 18:03:42 ON 28 OCT 2004

L1	1 S NIZATIDINE/CN
L2	1 S FAMOTIDINE/CN
L3	1 S CIMETIDINE/CN
L4	1 S RANITIDINE/CN
L5	1 S OLANZAPINE/CN
L6	1 S CLOZAPINE/CN
L7	1 S RISPERIDONE/CN
L8	0 S QUETIAPIN/CN
L9	1 S QUETIAPINE/CN
L10	0 S DIVALPROEX/CN
L11	1 S DIVALPROEX
L12	1 S MIRTAZAPINE/CN

FILE 'EMBASE, USPATFULL, CAPLUS, MEDLINE, IPA' ENTERED AT 18:05:17 ON 28 OCT 2004

L13	62859 S L1 OR L2 OR L3 OR L4 OR (H2 ANTAGONIST#) OR ZANTAC OR
TAGAMET	
L14	94740 S L5 OR L6 OR L7 OR L9 OR L11 OR L12 OR (PSYCHOTROPIC####
DRUG#	
L15	254 S 13 (20W) L14
L16	7 S L13 (20W) L14
L17	6 DUPLICATE REMOVE

L17 ANSWER 1 OF 6 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

ACCESSION NUMBER: 2003311229 EMBASE
TITLE: Current drug use as risk factor for erectile dysfunction:
Results from an Italian epidemiological study.
AUTHOR: Ricci E.; Parazzini F.; Mirone V.; Imbimbo C.; Palmieri
A.;
CORPORATE SOURCE: Bortolotti A.; Di Cintio E.; Landoni M.; Lavezzari M.
E. Ricci, Ist. di Ric. Farmacol. 'Mario Negri', via
Eritrea, Milano 62-20157, Italy. ricci@marionegri.it
SOURCE: International Journal of Impotence Research, (2003) 15/3
(221-224).
Refs: 17
ISSN: 0955-9930 CODEN: IJIRFB
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology
028 Urology and Nephrology
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English
SUMMARY LANGUAGE: English

AB . . . 1.4-6.9) and anticholinergic drugs (OR 12.8, 95% CI 2.7-60.1)
were associated with ED risk. No association emerged between ED and
H2 antagonists, anticholesterolemic or hypoglycemic
drugs. In conclusion, after taking account of related pathologies, our
results suggest that men treated with **antipsychotic**, diuretic
and anticholinergic drugs are at greater risk of ED.

L17 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:45096 CAPLUS
DOCUMENT NUMBER: 138:180577
TITLE: Glucose intolerance with atypical antipsychotics
AUTHOR(S): Hedenmalm, Karin; Hagg, Staffan; Stahl, Malin;
Mortimer, Orjan; Spigset, Olav
CORPORATE SOURCE: Drug Epidemiology Unit, Medical Products Agency,
Uppsala, Swed.
SOURCE: Drug Safety (2002), 25(15), 1107-1116
CODEN: DRSAEA; ISSN: 0114-5916
PUBLISHER: Adis International Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR
THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine
56-54-2, Quinidine 72-69-5, Nortriptyline 92-84-2D, Phenothiazine,
derivs. 113-53-1, Dosulepine 261-31-4D, Thioxanthene, derivs.
303-49-1, Clomipramine 315-72-0 438-60-8, Protriptyline 495-40-9D,
Butyrophenone, derivs. 1668-19-5, Doxepine 4498-32-2, Dibenzepine
7439-93-2, Lithium, biological studies 10262-69-8, Maprotiline
23047-25-8, Lofepramine 51481-61-9, Cimetidine 57574-09-1,
Amineptine 93413-69-5, Venlafaxine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(not assocd. with glucose intolerance with atypical

antipsychotic use; glucose intolerance with atypical
antipsychotics vs. conventional **antipsychotics** for
treatment of psychosis patients)

L17 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:881023 CAPLUS

DOCUMENT NUMBER: 134:33017

TITLE: Combination for treating weight gain associated with
antipsychotic use comprising an atypical

antipsychotic

and an H2 antagonist

INVENTOR(S): Todd, Jane Rogers

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000074784	A1	20001214	WO 2000-US9811	20000522
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1189662	A1	20020327	EP 2000-931932	20000522
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
PRIORITY APPLN. INFO.:			US 1999-138315P	P 19990609
			WO 2000-US9811	W 20000522

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

IT Antihistamines

(H2; atypical antipsychotic and **H2 antagonist**
combination for treating wt. gain assocd. with **antipsychotic**
therapy)

IT Drug delivery systems

(aerosols; atypical antipsychotic and **H2 antagonist**
combination for treating wt. gain assocd. with **antipsychotic**
therapy)

IT Antipsychotics

Body weight

(atypical antipsychotic and **H2 antagonist**
combination for treating wt. gain assocd. with **antipsychotic**
therapy)

IT Drug delivery systems

(capsules; atypical antipsychotic and **H2 antagonist**
combination for treating wt. gain assocd. with **antipsychotic**

therapy)

IT Drug delivery systems
(solns., i.v.; atypical antipsychotic and **H2 antagonist** combination for treating wt. gain assocd. with **antipsychotic** therapy)

IT Drug delivery systems
(suppositories; atypical antipsychotic and **H2 antagonist** combination for treating wt. gain assocd. with **antipsychotic** therapy)

IT Drug delivery systems
(suspensions; atypical antipsychotic and **H2 antagonist** combination for treating wt. gain assocd. with **antipsychotic** therapy)

IT Drug delivery systems
(tablets; atypical antipsychotic and **H2 antagonist** combination for treating wt. gain assocd. with **antipsychotic** therapy)

IT 5786-21-0, Clozapine **51481-61-9**, Cimetidine **66357-35-5**,
 , Ranitidine **76824-35-6**, Famotidine **76963-41-2**,
 Nizatidine 106266-06-2, Risperidone 106516-24-9, Sertindole
 111974-69-7, Quetiapine 132539-06-1, Olanzapine 146939-27-7,
 Ziprasidone
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study);
 USES
 (Uses)
 (atypical **antipsychotic** and **H2 antagonist**
 combination for treating wt. gain assocd. with **antipsychotic**
 therapy)

L17 ANSWER 4 OF 6 IPA COPYRIGHT 2004 ASHP on STN

ACCESSION NUMBER: 2001:6772 IPA
 DOCUMENT NUMBER: 38-06772
 TITLE: Drug interactions with cisapride: clinical implications
 AUTHOR: Landrum Michalets, E.; Rhinehart Williams, C.
 CORPORATE SOURCE: Mission + St. Joseph's Dept. of Pharm., 509 Biltmore Ave.,
 Asheville, NC 28801, USA Internet: msj.cphelm@memo.msj.org
 SOURCE: Clinical Pharmacokinetics (New Zealand), (Jul 2000) Vol.
 39, pp. 49-75. 257 Refs.
 CODEN: CPKNDH; ISSN: 0312-5963.
 DOCUMENT TYPE: General Review
 FILE SEGMENT: HUMAN
 LANGUAGE: English
 AB . . . and adverse effects of cisapride in combination with
 macrolide antibacterials, azole antifungal agents, antidepressants,
 antiretrovirals, grapefruit juice, antileukotrienes, calcium antagonists,
H2 antagonists, cardiac drugs, **antipsychotics**,
 and antibacterials, is presented.
 Tran Le

L17 ANSWER 5 OF 6 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
 on STN DUPLICATE 1

ACCESSION NUMBER: 93344779 EMBASE
 DOCUMENT NUMBER: 1993344779
 TITLE: Famotidine adjunctive pharmacotherapy for schizophrenia:
 Preliminary data.

AUTHOR: Deutsch S.I.; Rosse R.B.; Kendrick K.A.; Fay-McCarthy M.;
Collins Jr. J.P.; Wyatt R.J.
CORPORATE SOURCE: Dept. of Veterans Affairs Med. Ctr., Psychiatry Service,
50
SOURCE: Irving Street, N.W., Washington, DC 20422, United States
Clinical Neuropharmacology, (1993) 16/6 (518-524).
ISSN: 0362-5664 CODEN: CLNEDB
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 030 Pharmacology
032 Psychiatry
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English

AB The usefulness of the histamine-2 (H2) **antagonist**
famotidine as an adjunct to conventional **antipsychotic**
treatments of idiopathic psychotic disorders (i.e., schizophrenia and
schizoaffective disorder) was investigated in an open-label study. After
stabilization for at. . .

L17 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1992:207660 CAPLUS
DOCUMENT NUMBER: 116:207660
TITLE: Pharmacological comparison of the sigma recognition
site labelled by [3H]haloperidol in human and rat
cerebellum
AUTHOR(S): Barnes, J. M.; Barnes, N. M.; Barber, P. C.;
Champaneria, S.; Costall, B.; Hornsby, C. D.;
Ironsides, J. W.; Naylor, R. J.
CORPORATE SOURCE: Med. Sch., Univ. Birmingham, Birmingham, B15 2TT, UK
SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology
(1992),

345(2), 197-202

CODEN: NSAPCC; ISSN: 0028-1298

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 50-02-2, Dexamethasone 50-22-6, Corticosterone 50-23-7,

Hydrocortisone

50-52-2, Thioridazine 50-60-2, Phentolamine 51-55-8, Atropine,
biological studies 52-39-1, Aldosterone 56-12-2, GABA, biological
studies 56-40-6, Glycine, biological studies 57-83-0, Progesterone,
biological studies 58-22-0, Testosterone 58-25-3, Chlordiazepoxide
58-39-9, Perphenazine 59-33-6, Mepyrmine 60-26-4, Hexamethonium
69-23-8, Fluphenazine 77-10-1, PCP 86-01-1 97-39-2, DTG 359-83-1,
(+)-Pentazocine 361-37-5, Methysergide 465-65-6, Naloxone
525-66-6, Propranolol 749-02-0, Spiperone 2062-78-4, Pimozide
5786-21-0, Clozapine 7313-86-2, (-)Cyclazocine 7313-87-3

14198-28-8,

(-)SKF10,047 15676-16-1, Sulpiride 21500-98-1, TCP 34273-04-6
51152-91-1, (-)-Butaclamol 56245-67-1, (+)-Butaclamol 58640-82-7,
(+)SKF10,047 **66357-35-5**, Ranitidine 75859-04-0, Rimcazole
85976-54-1 87134-87-0, Sch 23390 maleate 90182-92-6, Zacopride
95417-67-7, L 687384

RL: BIOL (Biological study)

(binding of, to sigma recognition sites of human and rat cerebellum
membranes, **antipsychotic** activity and pathol. of psychosis in
relation to)